Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.59% is 43% below its 5-year average of -26.93%, near the low end of its 5-year range (-48.43%–-14.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.54% below its 12-month average of -27.85%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.59%.
RETURN ON EQUITY (ROE)
-38.59%
RETURN ON EQUITY (ROE) AVG TTM
-27.85%
RETURN ON EQUITY (ROE) AVG 3Y
-23.34%
RETURN ON EQUITY (ROE) AVG 5Y
-26.93%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-38.54%
CURRENT VS 3Y AVG
-65.35%
CURRENT VS 5Y AVG
-43.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+8.14%
vs the sector median at left
Vaxcyte, Inc.
Market Cap
$9.49B
Return on Equity (ROE)
-38.59%
TTM Avg
-27.85%
3Y Avg
-23.34%
5Y Avg
-26.93%
Market Cap
$9.34B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$9.22B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.60B
Return on Equity (ROE)
17.77%
TTM Avg
13.11%
3Y Avg
0.20%
5Y Avg
-3.65%
Market Cap
$9.64B
Return on Equity (ROE)
12.77%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
Market Cap
$8.95B
Return on Equity (ROE)
-230.05%
TTM Avg
-355.61%
3Y Avg
-251.82%
5Y Avg
-322.00%
Market Cap
$8.93B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$8.89B
Return on Equity (ROE)
9.85%
TTM Avg
9.79%
3Y Avg
-15.74%
5Y Avg
-21.41%
Market Cap
$9.95B
Return on Equity (ROE)
3.10%
TTM Avg
-8.94%
3Y Avg
-15.72%
5Y Avg
1.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.49B | -38.59% | -27.85% | -23.34% | -26.93% |
| Insulet Corp. (PODD)vs › | $9.34B | 26.39% | 25.41% | 19.99% | 14.02% |
| Bruker Corporation (BRKR)vs › | $9.22B | -2.97% | 3.00% | 15.91% | 17.66% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.60B | 17.77% | 13.11% | 0.20% | -3.65% |
| Henry Schein, Inc. (HSIC)vs › | $9.64B | 12.77% | 11.88% | 12.69% | 13.50% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.95B | -230.05% | -355.61% | -251.82% | -322.00% |
| Bruker Corporation (BRKRP)vs › | $8.93B | -2.97% | 3.00% | 15.91% | 17.66% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.89B | 9.85% | 9.79% | -15.74% | -21.41% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.95B | 3.10% | -8.94% | -15.72% | 1.14% |
| Repligen Corporation (RGEN)vs › | $9.95B | 1.97% | 0.51% | 3.14% | 3.97% |
ROE
-38.6%
ROA
-33.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.59% |
| 2026-03-31 | -31.59% |
| 2025-12-31 | -28.55% |
| 2025-09-30 | -22.72% |
| 2025-06-30 | -17.83% |
| 2025-03-31 | -15.93% |
| 2024-12-31 | -14.03% |
| 2024-09-30 | -14.85% |
| 2024-06-30 | -25.03% |
| 2024-03-31 | -22.02% |
| 2023-12-31 | -32.43% |
| 2023-09-30 | -21.35% |
| 2023-06-30 | -18.47% |
| 2023-03-31 | -25.93% |
| 2022-12-31 | -23.44% |
| 2022-09-30 | -48.43% |
| 2022-06-30 | -38.93% |
| 2022-03-31 | -32.78% |
| 2021-12-31 | -35.24% |
| 2021-09-30 | -30.15% |
| 2021-06-30 | -27.33% |
| 2021-03-31 | -25.48% |
| 2020-12-31 | -25.80% |
| 2020-09-30 | -23.70% |
| 2020-06-30 | -19.99% |
| 2020-03-31 | -48.56% |
